Amgen | Sustainability Performance
Develops and markets biopharmaceutical products for various medical conditions.
1980
United States
10,001+ employees
Biotechnology
$10B+ in revenue
$1B - 10B in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#430
Overallⓘ#103
in United Statesⓘ#5
in BiotechnologyⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Carbon emissionsCarbon certificatesDigital emissionsEnergy consumptionWaste ManagementWater ManagementNature and biodiversitySocial
Diversity and InclusionPay GapsHealth and SafetyExternalitiesGovernance
TargetsSDG ImpactFinancial Data
Business performanceCapital & innovationAnalyst projections
Leading
Aligned
Aligned
Aligned
Leading
Intensity
Greenhouse gas intensity Scope 1, 2 (tCO₂e /$M)
Greenhouse gas intensity (Scope 1, 2, 3)(tCO₂e /$M)
Energy consumption (direct) intensity (MWh /$M)
Industry Benchmark
7.5
B/M 10.8
55.3
B/M 128.6
28.3
B/M 27.9
Powered by illuminem and GIST Impact
Controversy level
- Amgen agreed to USD 762 million federal settlement in 2012, one of the largest pharmaceutical fraud cases, for offlabel marketing of Aranesp anemia drug and kickback payments to physicians, plus ongoing 340B drug pricing scrutiny.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
11+
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.